Zobrazeno 1 - 10
of 23
pro vyhledávání: '"S. P. Richman"'
Autor:
L E, Morrell, Y J, Lee, J, Hurley, M, Arias, C, Mies, S P, Richman, H, Fernandez, K A, Donofrio, W A, Raub, P A, Cassileth
Publikováno v:
Cancer. 82(3)
Traditionally, primary surgical therapy is considered unsuitable for the treatment of patients with locally advanced breast carcinoma (LABC). Multiple reports have documented the efficacy of primary chemotherapy in this group of patients. The purpose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1f90344056ec974032b4fa44b576524b
https://pubmed.ncbi.nlm.nih.gov/9452268
https://pubmed.ncbi.nlm.nih.gov/9452268
Autor:
B, Ardalan, A, Ucar, R, Reddy, A S, Livingstone, A, Markoe, J, Schwade, S P, Richman, K, Donofrio
Publikováno v:
Cancer. 74(7)
Preclinical and clinical data suggest that N-phosphonacetyl-L-aspartic acid (PALA) can augment the cytotoxic effects of 5-fluorouracil (5-FU). In addition, the combination of 5-FU and radiation therapy has been used with success in prolonging surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::af3f106607474060029a5c5efe599d2c
https://pubmed.ncbi.nlm.nih.gov/8082092
https://pubmed.ncbi.nlm.nih.gov/8082092
Publikováno v:
Cancer. 70(6)
4'-0-tetrahydropyranyladriamycin (Pirarubicin, Meiji Seika (USA) Inc., New York, NY) may be less toxic than doxorubicin.A Phase II trial of Pirarubicin was done in 26 patients who had not previously had chemotherapy and who had measurable and incurab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ffb5165e76f4cacd5b6524126a5e48a
https://pubmed.ncbi.nlm.nih.gov/1516010
https://pubmed.ncbi.nlm.nih.gov/1516010
Publikováno v:
Cancer. 67(2)
Adenocarcinoma of the pancreas is a highly lethal malignancy and chemotherapy has had little impact on the natural history of this disease. PALA, used to potentiate 5-fluorouracil (5-FU), has been shown to have synergy in vivo and in vitro. Twenty-se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c4c093e22904abbcc546229c776ea5c0
https://pubmed.ncbi.nlm.nih.gov/1985731
https://pubmed.ncbi.nlm.nih.gov/1985731
Autor:
K S, Sridhar, T S, Samy, R P, Agarwal, R C, Duncan, P, Benedetto, A G, Krishan, C L, Vogel, L G, Feun, N M, Savaraj, S P, Richman
Publikováno v:
Cancer. 66(10)
A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors. Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::64b822f33cf34ee2f17786ab8bbb237b
https://pubmed.ncbi.nlm.nih.gov/2224762
https://pubmed.ncbi.nlm.nih.gov/2224762
Autor:
Michael A. Burgess, Charles K. Tashima, Gabriel N. Hortobagyi, Robert B. Livingston, George R. Blumenschein, S. P. Richman, Evan M. Hersh, Aman U Buzdar, Jordan U. Gutterman
Publikováno v:
Cancer. 45:742-749
One hundred fifty-six evaluable patients with metastatic breast cancer were treated with vincristine, Adriamycin and cyclophosphamide alternating at fixed intervals with 5-FU and methotrexate. Immunotherapy with BCG or MER-BCG was administered to all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecee7eff9bd3af8ecd59a5258b06445e
https://doi.org/10.1002/1097-0142(19800215)45:4<742::aid-cncr2820450422>3.0.co
https://doi.org/10.1002/1097-0142(19800215)45:4<742::aid-cncr2820450422>3.0.co
Autor:
A K, Izumi, S P, Richman
Publikováno v:
Archives of Dermatology. 102:556-559
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e32456c54c8481e6af05a26c81276c7
https://doi.org/10.1001/archderm.102.5.556
https://doi.org/10.1001/archderm.102.5.556
Publikováno v:
JAMA: The Journal of the American Medical Association. 234:1233-1235
Because of the serious toxicity of intralesionally injected BCG, including high fever, local ulceration, chronic drainage, and disseminated BCG disease, 13 patients received local BCG immunotherapy by the new approach of epilesional scarification. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::481ea96bc610dd8eae9fc3a2869fc0ce
https://doi.org/10.1001/jama.234.12.1233
https://doi.org/10.1001/jama.234.12.1233
Autor:
M S, Blumenreich, T M, Woodcock, S P, Richman, M K, Jones, P S, Gentile, T T, Kubota, J C, Allegra
Publikováno v:
Cancer. 56(2)
Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::284a6492f1c451ad61875cc31c65155c
https://pubmed.ncbi.nlm.nih.gov/4005796
https://pubmed.ncbi.nlm.nih.gov/4005796
Autor:
V, Rodriguez, S P, Richman, R S, Benjamin, M A, Burgess, W K, Murphy, M, Valdivieso, R L, Banner, J U, Gutterman, G P, Bodey, E J, Freireich
Publikováno v:
Cancer research. 37(4)
One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b003ea7debbd2d4138d71e1813aa88ce
https://pubmed.ncbi.nlm.nih.gov/139205
https://pubmed.ncbi.nlm.nih.gov/139205